Abbott Laboratories
NYSE:ABT
Abbott Laboratories
Other Long-Term Assets
Abbott Laboratories
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Long-Term Assets
$16.5B
|
CAGR 3-Years
47%
|
CAGR 5-Years
50%
|
CAGR 10-Years
12%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Other Long-Term Assets
$2.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Long-Term Assets
$4.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
27%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Other Long-Term Assets
$1.7B
|
CAGR 3-Years
69%
|
CAGR 5-Years
44%
|
CAGR 10-Years
24%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Long-Term Assets
$3.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Long-Term Assets
$2.2B
|
CAGR 3-Years
30%
|
CAGR 5-Years
26%
|
CAGR 10-Years
29%
|
|
Abbott Laboratories
Glance View
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.
See Also
What is Abbott Laboratories's Other Long-Term Assets?
Other Long-Term Assets
16.5B
USD
Based on the financial report for Dec 31, 2024, Abbott Laboratories's Other Long-Term Assets amounts to 16.5B USD.
What is Abbott Laboratories's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
12%
Over the last year, the Other Long-Term Assets growth was 132%. The average annual Other Long-Term Assets growth rates for Abbott Laboratories have been 47% over the past three years , 50% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet